Latest On Zynerba Pharmaceuticals, Inc (ZYNE):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 16:58 EST | News | Zynerba Pharmaceuticals GAAP EPS of -$0.21 misses by $0.02 | N/A |  |
| 2023-03-28 14:10 EST | News | Zynerba Pharmaceuticals GAAP EPS of -$0.18 in-line | N/A | |
| 2023-03-13 21:08 EST | News | Zynerba Pharma says not holding cash deposits or securities at Silicon Valley Bank | N/A | |
| 2023-01-11 16:14 EST | News | Zynerba Pharma rises 6% on positive data from Fragile X syndrome treatment trial | N/A | |
| 2022-12-21 13:11 EST | News | Zynerba delaying release of late-stage top-line results for Fragile X syndrome candidate | N/A | |
| 2022-11-15 10:23 EST | News | Zynerba rises on orphan drug status for cannabidiol Zygel for 22q11.2 deletion syndrome in EU | N/A | |
| 2022-11-14 17:45 EST | News | Zynerba Pharmaceuticals GAAP EPS of -$0.20 beats by $0.03 | N/A | |
| 2022-11-03 01:21 EST | News | Zynerba gets US patent for cannabidiol Zygel to treat 22q11.2 Deletion Syndrome | N/A | |
| 2022-10-06 18:44 EST | News | Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome | N/A | |
| 2022-08-10 07:56 EST | News | Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01 | N/A | |
| 2022-07-22 07:36 EST | News | Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital | N/A | |
| 2022-06-22 10:22 EST | News | Zynerba stock rises as CBD gel improves rare disorder symptoms in trial; autism program deferred | N/A | |
| 2022-03-01 15:49 EST | News | Zynerba Pharmaceuticals GAAP EPS of -$0.22 beats by $0.04 | N/A | |
| 2022-02-28 22:18 EST | News | Zynerba Pharma gets orphan drug designation from European Commission for Zygel in FXS | N/A | |
| 2022-01-04 20:47 EST | News | Zynerba pushes back development of Zygel in a group of epilepsies | N/A | |
| 2021-11-22 13:25 EST | News | Zynerba Pharma pops 4% after securing new European patent for Zygel CBD gel | N/A | |
| 2021-11-15 15:43 EST | News | Zynerba Pharmaceuticals EPS misses by $0.01 | N/A | |
| 2021-11-11 16:10 EST | News | Revisiting Zynerba Pharmaceuticals | N/A | |
| 2021-09-22 11:45 EST | News | Zynerba Pharmaceuticals (ZYNE) Investor presentation - Slideshow | N/A | |
| 2021-09-09 15:03 EST | News | Zynerba Pharmaceuticals posts longer term data from Zygel autism study | N/A | |
| 2021-09-07 23:24 EST | News | Zynerba highlights results from mid-stage Zygel epilepsy study | N/A | |
| 2021-08-09 18:06 EST | News | Zynerba Pharmaceuticals EPS misses by $0.05 | N/A | |
| 2021-07-22 09:44 EST | News | Zynerba Pharmaceuticals (ZYNE) Presents At HealthVirtual Conference - Slideshow | N/A | |
| 2021-05-06 02:17 EST | News | Zynerba receives FDA guidance for Phase 3 trial design for Zygel in rare genetic disorder | N/A | |
| 2021-04-13 22:52 EST | News | Zynerba: Repeated Trial Failures, Some Post Hoc Success | N/A | |
| 2021-03-12 05:04 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 01:10 EST | Earnings Estimate | An EPS average of -$1.13 is estimated for the 2022 year. | Sell | |
| 2021-03-11 01:10 EST | Earnings Estimate | An EPS average of -$0.23 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-11 01:10 EST | Analyst Rating | The Analyst Target Price has increased from $7.25 to $7.29. | Buy | |
| 2021-03-10 22:03 EST | News | Zynerba Pharmaceuticals EPS in-line | N/A | |
| 2021-02-15 12:43 EST | Analyst Rating | The Analyst Target Price has decreased from $7.42 to $7.25. | Neutral | |
| 2021-02-07 02:02 EST | News | Marijuana as medicine: the other cannabinoid pharma players | N/A | |
| 2021-02-04 04:28 EST | News | Zogenix, Zynerba jump on positive read through from GW Pharma/Jazz (update) | N/A | |
| 2021-01-26 00:28 EST | News | Zeroing In On Zynerba Pharmaceuticals | N/A | |
| 2020-12-22 13:13 EST | Analyst Rating | The Analyst Target Price has decreased from $7.92 to $7.42. | Neutral | |
| 2020-12-21 13:23 EST | Analyst Rating | The Analyst Target Price has decreased from $9.67 to $7.92. | Neutral | |
| 2020-12-18 13:35 EST | Analyst Rating | The Analyst Target Price has decreased from $10 to $9.67. | Neutral | |
| 2020-12-18 02:52 EST | News | Zynerba expects to launch new Zygel trial before end of 2021, shares down 10% | N/A | |
| 2020-12-17 08:48 EST | News | Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome | N/A | |
| 2020-11-26 22:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-21 08:37 EST | News | Seeking Alpha Catalyst Watch | N/A | |
| 2020-11-11 05:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-10 13:34 EST | Earnings Estimate | An EPS average of -$0.38 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-09 23:47 EST | News | Zynerba Pharmaceuticals EPS beats by $0.12 | N/A | |
| 2020-11-08 01:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 06:22 EST | News | Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback | N/A | |
| 2020-10-16 06:20 EST | News | New data shows Zynerba's ZYN002 positive effect in autism study | N/A | |
| 2020-09-26 14:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 04:38 EST | News | Zynerba Pharmaceuticals - Whether They've Cracked The Code For Fully Methylated FX Syndrome Patients | N/A | |
About Zynerba Pharmaceuticals, Inc (ZYNE):
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
General
- Name Zynerba Pharmaceuticals, Inc
- Symbol ZYNE
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 26
- Fiscal Year EndDecember
- IPO Date2015-08-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://zynerba.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 1152.69
- Price/Book (Most Recent Quarter) 3.51
- Enterprise Value Revenue 397.61
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.02
- Next Year EPS Estimate -$1.13
- Next Quarter EPS Estimate -$0.32
- Return on Assets -40%
- Return on Equity -76%
- Revenue 86000
- Earnings Per Share -$1.89
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 214.92 million
- EBITDA -36895716
- Analyst Target Price $7.29
- Book Value Per Share $2.02
View More
Share Statistics
- Shares Outstanding 41.25 million
- Shares Float 40.16 million
- % Held by Insiders 711%
- % Held by Institutions 22.03%
- Shares Short 2.99 million
- Shares Short Prior Month 3.2 million
- Short Ratio 0.25
- Short % of Float 11%
- Short % of Shares Outstanding 10%
View More
Technicals
- Beta 2.82
- 52 Week High $9
- 52 Week Low $3.11
- 50 Day Moving Average 4.92
- 200 Day Moving Average 4.01
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Zynerba Pharmaceuticals, Inc (ZYNE) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Zynerba Pharmaceuticals, Inc (ZYNE) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-10 | $N/A | -$0.33 | -$0.33 | -0.43% |
| 2020-09-30 | 2020-11-09 | $N/A | -$0.31 | -$0.43 | 28.39% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.78 | -$0.45 | -74.46% |
| 2020-03-31 | 2020-05-11 | $N/A | -$0.53 | -$0.50 | -6.62% |
| 2019-12-31 | 2020-03-10 | $N/A | -$0.46 | -$0.51 | 9.29% |
| 2019-09-30 | 2019-11-06 | $N/A | -$0.08 | -$0.52 | 84.66% |
| 2019-06-30 | 2019-08-06 | $N/A | -$0.50 | -$0.49 | -1.52% |
| 2019-03-31 | 2019-05-08 | $N/A | -$0.47 | -$0.49 | 3.75% |
| 2018-12-31 | 2019-03-11 | $86000 | -$0.44 | -$0.66 | 33% |
| 2018-09-30 | 2018-11-08 | $N/A | -$0.47 | -$0.67 | 29.85% |
| 2018-06-30 | 2018-08-02 | $N/A | -$0.89 | -$0.74 | -20.27% |
| 2018-03-31 | 2018-05-08 | $N/A | -$0.91 | -$0.63 | -45.02% |
| 2017-12-31 | 2018-03-12 | $N/A | -$0.60 | -$0.60 | 0.28% |
| 2017-09-30 | 2017-11-14 | $N/A | -$0.63 | -$0.60 | -4.56% |
| 2017-06-30 | 2017-08-01 | $N/A | -$0.64 | -$0.59 | -8.47% |
| 2017-03-31 | 2017-05-09 | $N/A | -$0.60 | -$0.56 | -7.62% |
| 2016-12-31 | 2017-03-27 | $7250 | -$0.71 | -$0.66 | -6.93% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.67 | -$0.55 | -21.82% |
| 2016-06-30 | 2016-08-11 | $-7000 | -$0.70 | -$0.50 | -41.41% |
| 2016-03-31 | 2016-05-12 | $7000 | -$0.49 | -$0.56 | 11.71% |
| 2015-12-31 | 2016-03-14 | $49000 | -$0.62 | -$0.50 | -24% |
| 2015-09-30 | 2015-11-11 | $200000 | -$0.66 | -$0.38 | -73.68% |
| 2015-06-30 | 2015-08-05 | $15000 | -$0.18 |
Zynerba Pharmaceuticals, Inc (ZYNE) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Zynerba Pharmaceuticals, Inc (ZYNE) Chart:
Zynerba Pharmaceuticals, Inc (ZYNE) News:
Below you will find a list of latest news for Zynerba Pharmaceuticals, Inc (ZYNE) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Zynerba Pharmaceuticals, Inc (ZYNE) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.05 | CALL | 0 | 279 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.4 | PUT | 0 | 11 | 151.8 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 564.06 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 429.83 | TRUE | 0 | 0 |
Latest ZYNE Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 100 | $1.015 |
| Jun 13, 2022 7:59 PM EST | 2 | $1.015 |
| Jun 13, 2022 7:59 PM EST | 2 | $1.015 |
| Jun 13, 2022 7:59 PM EST | 2 | $1.015 |
| Jun 13, 2022 7:59 PM EST | 1 | $1.015 |
Zynerba Pharmaceuticals, Inc (ZYNE) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920078403/0001104659-20-078403-index.htm |
| 2019-08-08 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1621443/000000000019012187/0000000000-19-012187-index.htm |
| 2020-02-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000083423720008152/0000834237-20-008152-index.htm |
| 2020-07-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000083423720009919/0000834237-20-009919-index.htm |
| 2019-04-25 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1621443/000104746919002558/0001047469-19-002558-index.htm |
| 2018-06-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918038780/0001104659-18-038780-index.htm |
| 2018-07-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918043916/0001104659-18-043916-index.htm |
| 2018-07-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918044210/0001104659-18-044210-index.htm |
| 2018-07-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918044790/0001104659-18-044790-index.htm |
| 2018-07-19 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1621443/000110465918046019/0001104659-18-046019-index.htm |
| 2018-07-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918046020/0001104659-18-046020-index.htm |
| 2018-07-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1621443/000110465918046315/0001104659-18-046315-index.htm |
| 2018-07-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918046317/0001104659-18-046317-index.htm |
| 2018-08-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918048964/0001104659-18-048964-index.htm |
| 2018-09-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918055197/0001104659-18-055197-index.htm |
| 2018-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918059546/0001104659-18-059546-index.htm |
| 2018-11-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918066802/0001104659-18-066802-index.htm |
| 2018-12-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918072585/0001104659-18-072585-index.htm |
| 2018-12-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465918073196/0001104659-18-073196-index.htm |
| 2019-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919000679/0001104659-19-000679-index.htm |
| 2019-02-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919009430/0001104659-19-009430-index.htm |
| 2019-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919010499/0001104659-19-010499-index.htm |
| 2019-03-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919013241/0001104659-19-013241-index.htm |
| 2019-03-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919013709/0001104659-19-013709-index.htm |
| 2019-03-11 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1621443/000110465919013754/0001104659-19-013754-index.htm |
| 2019-04-25 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1621443/000110465919023594/0001104659-19-023594-index.htm |
| 2019-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919026966/0001104659-19-026966-index.htm |
| 2019-05-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919027154/0001104659-19-027154-index.htm |
| 2019-05-06 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1621443/000110465919027157/0001104659-19-027157-index.htm |
| 2019-05-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919027667/0001104659-19-027667-index.htm |
| 2019-05-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919032197/0001104659-19-032197-index.htm |
| 2019-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919035052/0001104659-19-035052-index.htm |
| 2019-08-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919044130/0001104659-19-044130-index.htm |
| 2019-08-06 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1621443/000110465919044150/0001104659-19-044150-index.htm |
| 2019-08-09 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1621443/000110465919045135/0001104659-19-045135-index.htm |
| 2019-08-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919048256/0001104659-19-048256-index.htm |
| 2019-08-30 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1621443/000110465919048268/0001104659-19-048268-index.htm |
| 2019-09-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919050481/0001104659-19-050481-index.htm |
| 2019-09-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919051099/0001104659-19-051099-index.htm |
| 2019-11-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465919060256/0001104659-19-060256-index.htm |
| 2020-01-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920003213/0001104659-20-003213-index.htm |
| 2020-02-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920009482/0001104659-20-009482-index.htm |
| 2020-02-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000110465920016335/0001104659-20-016335-index.htm |
| 2020-02-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920024469/0001104659-20-024469-index.htm |
| 2020-02-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920025024/0001104659-20-025024-index.htm |
| 2020-03-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920028362/0001104659-20-028362-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920030972/0001104659-20-030972-index.htm |
| 2020-03-10 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1621443/000110465920031380/0001104659-20-031380-index.htm |
| 2020-04-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920046587/0001104659-20-046587-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1621443/000110465920050049/0001104659-20-050049-index.htm |
| 2020-04-23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1621443/000110465920050053/0001104659-20-050053-index.htm |
| 2020-05-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920059089/0001104659-20-059089-index.htm |
| 2020-05-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1621443/000110465920064527/0001104659-20-064527-index.htm |
| 2020-05-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920065620/0001104659-20-065620-index.htm |
| 2020-05-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920066085/0001104659-20-066085-index.htm |
| 2020-06-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920068652/0001104659-20-068652-index.htm |
| 2020-06-02 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920068926/0001104659-20-068926-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920072407/0001104659-20-072407-index.htm |
| 2020-06-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920078403/0001104659-20-078403-index.htm |
| 2020-07-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920085391/0001104659-20-085391-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920092358/0001104659-20-092358-index.htm |
| 2020-09-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920104585/0001104659-20-104585-index.htm |
| 2020-09-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920106099/0001104659-20-106099-index.htm |
| 2020-10-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1621443/000110465920115292/0001104659-20-115292-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000271/0001192482-18-000271-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000272/0001192482-18-000272-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000273/0001192482-18-000273-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000274/0001192482-18-000274-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000275/0001192482-18-000275-index.htm |
| 2018-06-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000276/0001192482-18-000276-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000330/0001192482-18-000330-index.htm |
| 2018-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000331/0001192482-18-000331-index.htm |
| 2018-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000383/0001192482-18-000383-index.htm |
| 2018-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000384/0001192482-18-000384-index.htm |
| 2018-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000385/0001192482-18-000385-index.htm |
| 2018-08-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000386/0001192482-18-000386-index.htm |
| 2018-08-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000409/0001192482-18-000409-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000453/0001192482-18-000453-index.htm |
| 2018-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000455/0001192482-18-000455-index.htm |
| 2019-01-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000007/0001192482-19-000007-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000047/0001192482-19-000047-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000048/0001192482-19-000048-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000049/0001192482-19-000049-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000050/0001192482-19-000050-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000051/0001192482-19-000051-index.htm |
| 2019-01-30 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000063/0001192482-19-000063-index.htm |
| 2019-02-20 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000098/0001192482-19-000098-index.htm |
| 2019-02-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000100/0001192482-19-000100-index.htm |
| 2019-04-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000184/0001192482-19-000184-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000280/0001192482-19-000280-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000282/0001192482-19-000282-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000284/0001192482-19-000284-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000286/0001192482-19-000286-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000288/0001192482-19-000288-index.htm |
| 2019-06-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000290/0001192482-19-000290-index.htm |
| 2019-07-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000310/0001192482-19-000310-index.htm |
| 2019-10-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000364/0001192482-19-000364-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000087/0001192482-20-000087-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000089/0001192482-20-000089-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000091/0001192482-20-000091-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000093/0001192482-20-000093-index.htm |
| 2020-02-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000095/0001192482-20-000095-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000463/0001192482-20-000463-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000465/0001192482-20-000465-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000467/0001192482-20-000467-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000469/0001192482-20-000469-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000471/0001192482-20-000471-index.htm |
| 2020-06-11 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1621443/000119248220000473/0001192482-20-000473-index.htm |
| 2019-12-02 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000121390019025094/0001213900-19-025094-index.htm |
| 2020-05-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000121390020011593/0001213900-20-011593-index.htm |
| 2019-01-29 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000149315219001070/0001493152-19-001070-index.htm |
| 2018-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837018006158/0001558370-18-006158-index.htm |
| 2018-11-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837018008905/0001558370-18-008905-index.htm |
| 2019-03-11 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1621443/000155837019001742/0001558370-19-001742-index.htm |
| 2019-05-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837019004373/0001558370-19-004373-index.htm |
| 2019-08-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837019007148/0001558370-19-007148-index.htm |
| 2019-11-06 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837019010074/0001558370-19-010074-index.htm |
| 2020-03-10 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1621443/000155837020002280/0001558370-20-002280-index.htm |
| 2020-05-11 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837020006117/0001558370-20-006117-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1621443/000155837020010072/0001558370-20-010072-index.htm |
| 2019-01-15 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000161577419000650/0001615774-19-000650-index.htm |
| 2019-06-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1621443/000161577419009100/0001615774-19-009100-index.htm |
| 2019-08-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1621443/999999999519001874/9999999995-19-001874-index.htm |
Zynerba Pharmaceuticals, Inc (ZYNE) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zynerba Pharmaceuticals, Inc (ZYNE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 711%Institutional Ownership: 2203%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2018-08-06 | Terri B Sebree | President | Buy | 3,800.00 | 5.79 | 22,013.40 | 182,546.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000384/0001192482-18-000384-index.htm |
| 2019-01-24 | Terri B Sebree | President | Buy | 3,600.00 | 186,146.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248219000050/0001192482-19-000050-index.htm | ||
| 2018-08-06 | James E Fickenscher | Chief Financial Officer | Buy | 8,518.00 | 5.97 | 50,842.24 | 20,718.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000383/0001192482-18-000383-index.htm |
| 2018-08-06 | ARMANDO ANIDO | Chairman & Chief Exec. Officer | Buy | 15,000.00 | 5.96 | 89,422.50 | 352,512.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000386/0001192482-18-000386-index.htm |
| 2018-08-06 | Suzanne M. Hanlon | Sec, VP & General Counsel | Buy | 3,800.00 | 5.80 | 22,047.60 | 43,693.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000385/0001192482-18-000385-index.htm |
| 2018-08-22 | John P. Butler | Director | Buy | 5,000.00 | 6.43 | 32,153.00 | 5,000.00 | https://www.sec.gov/Archives/edgar/data/1621443/000119248218000409/0001192482-18-000409-index.htm |